GRAFT VERSUS HOST DISEASE
Clinical trials for GRAFT VERSUS HOST DISEASE explained in plain language.
Never miss a new study
Get alerted when new GRAFT VERSUS HOST DISEASE trials appear
Sign up with your email to follow new studies for GRAFT VERSUS HOST DISEASE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for GVHD patients who failed first drug
Disease control CompletedThis study tested a drug called nilotinib in 65 adults with chronic graft-versus-host disease (GVHD), a complication after a stem cell transplant where donor cells attack the patient's body. Participants had already tried imatinib without success. The goal was to see if nilotinib…
Matched conditions: GRAFT VERSUS HOST DISEASE
Phase: PHASE2 • Sponsor: University Hospital, Lille • Aim: Disease control
Last updated May 14, 2026 12:04 UTC
-
Lower drug dose may prevent transplant complications without extra risk
Disease control CompletedThis study tested whether a lower dose of a drug called cyclophosphamide could prevent graft-versus-host disease (GVHD) in 35 adults receiving stem cell transplants for blood cancers or disorders. GVHD is a serious side effect where donor cells attack the patient's body. The lowe…
Matched conditions: GRAFT VERSUS HOST DISEASE
Phase: PHASE2 • Sponsor: Hospital Universitario Dr. Jose E. Gonzalez • Aim: Disease control
Last updated May 12, 2026 13:42 UTC
-
Stem cells show promise for deadly transplant complication
Disease control CompletedThis study tested a stem cell treatment called Prochymal in 11 people with severe graft-versus-host disease (GVHD), a life-threatening complication after a bone marrow transplant. The treatment was given to patients whose GVHD did not improve with standard therapies. The goal was…
Matched conditions: GRAFT VERSUS HOST DISEASE
Phase: PHASE2 • Sponsor: Mesoblast, Inc. • Aim: Disease control
Last updated May 11, 2026 20:54 UTC
-
New drug combo shows promise in preventing transplant complications
Disease control CompletedThis early-phase study tested whether adding a drug called BMS-986004 (which blocks CD40-L) to standard immune-suppressing medicine could help prevent acute graft-versus-host disease (GVHD) in 45 adults with blood cancers or disorders receiving a stem cell transplant. GVHD is a s…
Matched conditions: GRAFT VERSUS HOST DISEASE
Phase: PHASE1 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated May 11, 2026 20:48 UTC
-
Light therapy may shield transplant patients from dangerous immune attack
Disease control CompletedThis study tested whether a procedure called extracorporeal photophoresis (ECP) could prevent graft-versus-host disease (GVHD) in 158 people receiving stem cell transplants for blood cancers. ECP involves treating a patient's blood with light before returning it to the body. The …
Matched conditions: GRAFT VERSUS HOST DISEASE
Phase: NA • Sponsor: Oslo University Hospital • Aim: Disease control
Last updated May 08, 2026 12:01 UTC
-
New hope for stem cell transplant patients: drug targets stubborn GvHD
Disease control CompletedThis study tested a drug called pomalidomide in 34 adults with chronic graft-versus-host disease (GvHD), a condition where donor immune cells attack the recipient's body after a stem cell transplant. Participants had GvHD that did not improve with standard treatments. They took p…
Matched conditions: GRAFT VERSUS HOST DISEASE
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 01, 2026 15:57 UTC
-
Can a lupus drug stop transplant complications?
Disease control CompletedThis early study tested the drug belimumab (Benlysta) in 10 adults who had a stem cell transplant for blood cancer. The goal was to see if it could safely prevent chronic graft-versus-host disease (GvHD), a serious long-term complication where donor cells attack the patient's bod…
Matched conditions: GRAFT VERSUS HOST DISEASE
Phase: PHASE1 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated Apr 26, 2026 20:00 UTC
-
New imaging tracer may help detect dangerous transplant complication
Knowledge-focused CompletedThis early-phase study tested a new imaging tracer called [18F]F-AraG in 9 patients who had or were at high risk for graft-versus-host disease (GVHD) after a stem cell transplant. The tracer is designed to highlight activated T cells, which cause GVHD. Researchers compared the PE…
Matched conditions: GRAFT VERSUS HOST DISEASE
Phase: PHASE1 • Sponsor: CellSight Technologies, Inc. • Aim: Knowledge-focused
Last updated May 07, 2026 18:41 UTC